News for Seagen Inc. (SGEN)

NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.( TARA), a clinical-stage company developing transformative therapies for the treatment

**media[596099]**

Though the stock market is still historically pricey, a few phenomenal bargains have cropped up.

Try not to let market volatility bring you down. Instead, let dividend stocks make you happy. These high-yield dividend stocks will pay you between 3% and 7% to hold them.

Buying stock in great companies when they are dealing with some short-term issue that creates stock price weakness can set investors up for big gains down the road. As long as the business is still in good shape, adding it to your portfolio when it's trading at a sizable discount can look like a brilliant move in the future. Stocks normally trade at discounts when there are concerns or question marks about the company's future performance.

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, to

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China's National Medical Products Administration (NMPA) has accepted the Biologics License Appl

/PRNewswire-PRWeb/ -- Ambrosia Biosciences Inc. ("Ambrosia"), today announced the appointment of Jason Haddock to the Board of Directors and as Chair of the...

We recently published a list of 10 Best Very Cheap Stocks To Buy Right Now. In this article, we are going to take a look at where Pfizer Inc.

The overall market atmosphere has been moderately negative since the new tariffs from the US.

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced positive topline results from the China subpopulation of the global Phase 3 innovaTV 301 study, demo

Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer

Biocom California Appoints New Members to its Board of Directors

A new year brings with it new opportunities to grow your wealth on Wall Street.

These value, growth, and income stocks are incredibly cheap in a historically pricey stock market.

Most of these stocks have a solid earnings track record (except for the clinical-stage biotech that doesn't yet generate product revenue). A key catalyst is unfolding right now: This top artificial intelligence (AI) chip designer is ramping production of its Blackwell architecture, and demand is

Aadi Bioscience Transforms with In-Licensing of Novel ADC Portfolio, $100 Million Sale of FYARRO ® and $100 Million PIPE Financing

PESG Research Releases an Market Update Report on [url="]Silexion Therapeutics (NASDAQ: SLXN)[/url]. The precision oncology sector has rapidly evolved into one

Pharmaceutical and biotech stocks often are seen as steady and safe options for investors for one particular reason. Drugmakers often see phases of growth as they develop candidates for a high-potential treatment area or as they launch promising new products. Over time, you can benefit from these periods by buying shares of certain biotech and pharma companies and holding for the long term.